IVIg Treatment and Plasma Cells in Guillain-Barré Syndrome
Author Information
Author(s): Mori Izumi, Parizot Christophe, Dorgham Karim, Demeret Sophie, Amoura Zahir, Bolgert Francis, Gorochov Guy
Primary Institution: Institut National de la Santé et de la Recherche Médicale (INSERM) U543, Paris, France
Hypothesis
Can the mobilization of plasma cells after IVIg treatment predict clinical improvement in Guillain-Barré Syndrome?
Conclusion
Prominent plasma-cell mobilization after IVIg treatment is associated with faster recovery in Guillain-Barré Syndrome patients.
Supporting Evidence
- IVIg treatment led to a significant increase in plasma cell counts in patients with Guillain-Barré Syndrome.
- Patients with higher plasma cell counts on day 7 of IVIg treatment showed faster clinical improvement.
- The study included both retrospective and prospective analyses to confirm findings.
- Plasma cell mobilization was not observed in patients treated with plasma exchange or those receiving no treatment.
Takeaway
When patients with Guillain-Barré Syndrome receive IVIg treatment, their body makes more plasma cells, and this helps them get better faster.
Methodology
The study involved retrospective and prospective analyses of blood samples from patients with autoimmune diseases treated with IVIg, measuring plasma cell counts and correlating them with clinical outcomes.
Potential Biases
Potential biases may arise from the retrospective nature of part of the analysis and the selection of participants.
Limitations
The study primarily focused on specific autoimmune diseases and may not generalize to all conditions treated with IVIg.
Participant Demographics
The study included 50 GBS patients (31 men, 19 women) with a median age of 57 years, and other autoimmune patients with varying demographics.
Statistical Information
P-Value
p=0.0031
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website